S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Alphatec Stock Forecast, Price & News

-0.30 (-2.71%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.45 million shs
Average Volume
777,506 shs
Market Capitalization
$1.07 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for Alphatec and its competitors with MarketBeat's FREE daily newsletter.

Alphatec logo

About Alphatec

Alphatec Holdings, Inc. engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings. The company was founded on March 4, 2005 and is headquartered in Carlsbad, CA.


The Goldman Sachs Group Begins Coverage on Alphatec (NASDAQ:ATEC)
December 3, 2021 |  americanbankingnews.com
Alphatec (NASDAQ:ATEC) Hits New 52-Week Low at $10.31
December 2, 2021 |  americanbankingnews.com
Alphatec Holdings, Inc. (NASDAQ:ATEC) SVP Sells $73,687.50 in Stock
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Health Care Equipment
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$144.86 million
Book Value
$1.13 per share


Net Income
$-78.99 million
Pretax Margin




Free Float
Market Cap
$1.07 billion
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)

Social Links


Overall MarketRank

2.42 out of 5 stars

Medical Sector

181st out of 1,388 stocks

Surgical & Medical Instruments Industry

23rd out of 126 stocks

Analyst Opinion: 3.4Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -

Alphatec (NASDAQ:ATEC) Frequently Asked Questions

Is Alphatec a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Alphatec stock.
View analyst ratings for Alphatec
or view top-rated stocks.

How has Alphatec's stock price been impacted by Coronavirus (COVID-19)?

Alphatec's stock was trading at $4.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ATEC shares have increased by 143.8% and is now trading at $10.75.
View which stocks have been most impacted by COVID-19

Are investors shorting Alphatec?

Alphatec saw a decrease in short interest in November. As of November 15th, there was short interest totaling 5,210,000 shares, a decrease of 20.2% from the October 31st total of 6,530,000 shares. Based on an average daily trading volume, of 963,700 shares, the short-interest ratio is currently 5.4 days. Approximately 8.4% of the shares of the company are short sold.
View Alphatec's Short Interest

When is Alphatec's next earnings date?

Alphatec is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Alphatec

How were Alphatec's earnings last quarter?

Alphatec Holdings, Inc. (NASDAQ:ATEC) issued its earnings results on Thursday, November, 4th. The medical technology company reported ($0.43) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by $0.20. The medical technology company had revenue of $62.88 million for the quarter, compared to analysts' expectations of $61.43 million. Alphatec had a negative trailing twelve-month return on equity of 92.96% and a negative net margin of 61.41%. During the same quarter last year, the firm posted ($0.18) earnings per share.
View Alphatec's earnings history

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $235 million-$235 million, compared to the consensus revenue estimate of $233.93 million.

What price target have analysts set for ATEC?

7 brokerages have issued 12-month price objectives for Alphatec's stock. Their forecasts range from $12.50 to $24.00. On average, they expect Alphatec's stock price to reach $19.63 in the next year. This suggests a possible upside of 82.6% from the stock's current price.
View analysts' price targets for Alphatec
or view top-rated stocks among Wall Street analysts.

Who are Alphatec's key executives?

Alphatec's management team includes the following people:
  • Patrick S. Miles, Chairman, President, CEO & COO (LinkedIn Profile)
  • J. Todd Koning, Chief Financial Officer & Executive Vice President
  • Luiz Pimenta, Chief Medical Officer
  • Scott Lish, Senior Vice President-Research & Development (LinkedIn Profile)
  • Michael T. Dendinger, Vice President-Operations

What is Pat Miles' approval rating as Alphatec's CEO?

7 employees have rated Alphatec CEO Pat Miles on Glassdoor.com. Pat Miles has an approval rating of 72% among Alphatec's employees.

What other stocks do shareholders of Alphatec own?

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Who are Alphatec's major shareholders?

Alphatec's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.77%), Deerfield Management Company L.P. Series C (3.62%), Point72 Asset Management L.P. (3.08%), Next Century Growth Investors LLC (1.82%), Cerity Partners LLC (1.58%) and Geode Capital Management LLC (1.19%). Company insiders that own Alphatec stock include Craig E Hunsaker, David H Mowry, David R Pelizzon, David Sponsel, Evan Bakst, James L L Tullis, James L L Tullis, Jeffrey G Black, Jeffrey P Rydin, Jennifer N Pritzker, Jennifer N Pritzker, Patrick Miles, Paul Segal and Scott Lish.
View institutional ownership trends for Alphatec

Which major investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Principal Financial Group Inc., Pier Capital LLC, BlackRock Inc., Renaissance Technologies LLC, Macquarie Group Ltd., Assenagon Asset Management S.A., and Russell Investments Group Ltd.. Company insiders that have sold Alphatec company stock in the last year include Craig E Hunsaker, David H Mowry, David Sponsel, James L L Tullis, Jeffrey G Black, and Scott Lish.
View insider buying and selling activity for Alphatec
or view top insider-selling stocks.

Which major investors are buying Alphatec stock?

ATEC stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Janus Henderson Group PLC, King Luther Capital Management Corp, Royal Bank of Canada, CastleArk Alternatives LLC, Deutsche Bank AG, Dimensional Fund Advisors LP, and Mercer Global Advisors Inc. ADV. Company insiders that have bought Alphatec stock in the last two years include Craig E Hunsaker, David R Pelizzon, David Sponsel, Evan Bakst, Jennifer N Pritzker, Patrick Miles, and Paul Segal.
View insider buying and selling activity for Alphatec
or or view top insider-buying stocks.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $10.75.

How much money does Alphatec make?

Alphatec has a market capitalization of $1.07 billion and generates $144.86 million in revenue each year. The medical technology company earns $-78.99 million in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does Alphatec have?

Alphatec employs 296 workers across the globe.

When was Alphatec founded?

Alphatec was founded in 1990.

What is Alphatec's official website?

The official website for Alphatec is www.atecspine.com.

Where are Alphatec's headquarters?

Alphatec is headquartered at 5818 EL CAMINO REAL, CARLSBAD CA, 92008.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at (760) 431-9286, via email at [email protected], or via fax at 800-922-1356.

This page was last updated on 12/6/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.